after much contemplation, I finally got around to prepping PFtek jars with 15 mM MiPT (made from tryptamine, derived from tryptophan) as an experimental group, and a control group without MiPT. Characterization will be by HPLC-UV-MS.
-
Members of the previous forum can retrieve their temporary password here, (login and check your PM).
Biotransformation of MiPT to 4-HO-MiPT
- Thread starter benzyme
- Start date
Would this work as well with organisms that produce bufotenin?
downwardsfromzero
Boundary condition
Maybe not. The 5-hydroxylation of tryptophan occurs before decarboxylation in that pathway, I think. Not much is known about the isopropyl analogue of bufotenine.dragonrider said:
Thanks for the support. It's been discussed before, I'm just fortunate of having the means of characterizing the end products. LCMS determination of psilocin/psilocybin in mushrooms is something I'm no stranger to, and I have spectra for the MiPT.
welp, those spores were nonviable. I just innoc'd some jars with a new syringe (most vendors have opted for syringes vs. prints), with 20 mM MiPT, and a control jar.
I also ordered a syringe, and a print, of c.cyanescens. That species may particularly have stronger expression of PsiH, a gene which encodes for tryptamine-4-monooxygenase (a CYP450 enzyme, nonspecific oxidoreductase). Said gene was only recently characterized, by Fricke et. al, 2017.
I also ordered a syringe, and a print, of c.cyanescens. That species may particularly have stronger expression of PsiH, a gene which encodes for tryptamine-4-monooxygenase (a CYP450 enzyme, nonspecific oxidoreductase). Said gene was only recently characterized, by Fricke et. al, 2017.
RoundAbout
Rising Star
I guess the main peak in the control is a fragment from the alpha cleavage of psilocybin, but what are the main peaks in the experimental? Out of curiousity...
RoundAbout said:
your guess is as good as mine. I didn't run any standards